Claims

1) A compound of Formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

the ring containing X and Y is a pyrrole and X is NH and Y is CH or X is CH and Y is NH;

Z is selected from CH, CF, CCl or, if Q is not N, N;

Q is selected from CH, CF, CCl or, if Z is not N, N;

m is 0, 1 or 2;

n is 0, 1 or 2;

p is 1 or 2;

R^1 is in each occurrence independently selected from F, Cl, CN, Me, CF_3, C_1-C_3 alkyl, cyclopropyl, C_1-C_3 fluoroalkyl, OMe or C_1-C_3 alkoxy;

R^2 is in each occurrence independently selected from F, Cl, Me, MeO and CF_3;

R^3 is H, Me, C_1-C_3 alkyl or C_1-C_3 fluoroalkyl;

R^4 is H, Me or C_1-C_3 alkyl;

R^5 is H, Me, C_1-C_3 alkyl, C_1-C_3 fluoroalkyl, CH_2OMe, CH_2OCHF_2, CH_2OCF_3, $CH_2O(C_1$-C_3 alkyl), $CH_2O(C_1$-C_3 fluoroalkyl), $C(CH_2CH_2)R^6$, CCR^7, CH_2R^8, R^9 or CH_2R^{10};

R^6 is H, Me, CH_2F, CHF_2, CF_3, CH_2OH or CH_2OMe;

R^7 is H, Me, cyclopropyl, C_1-C_3 alkyl, C_1-C_3 fluoroalkyl, C_3-C_6 cycloalkyl or a 5-membered heteroaryl group optionally substituted with Me, C_1-C_3 alkyl, F or Cl;

R^8 is a 5-membered heteroaryl optionally substituted with Me, C_1-C_3 alkyl, F or Cl;

R^9 is an optionally substituted phenyl, 5- or 6-membered heteroaryl, or bicyclic heteroaryl group; and

R^{10} is an optionally substituted phenyl, 5- or 6-membered heteroaryl, or bicyclic heteroaryl group.

2) The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein Y is N.

3) The compound or pharmaceutically acceptable salt thereof according to claim 1 wherein X is N.

4) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein p is 1.

5) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein Z is CF and Q is CH, CF or CCl.

6) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein m is 1 or 2 and wherein at least one R^1 group is F.

7) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein R^3 is H.

8) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein n is 0.

9) The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein R^5 is R^9.

10) The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 8, wherein R^5 is CH_2R^8 or CH_2R^{10}.

11) The compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 8, wherein R^5 is CCR^7.

12) The compound or pharmaceutically acceptable salt thereof according to claim 1, selected from:

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(4-fluorobenzyl)spiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(but-2-yn-1-yl)-5-fluorospiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(prop-2-yn-1-yl)spiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(3-(1-methyl-1H-pyrazol-4-yl)prop-2-yn-1-yl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-4-((2-((5-amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-2',3-dioxospiro [isoindoline-1,3'-pyrrolidin]-1'-yl)methyl)-2-fluorobenzonitrile;

(S)-1'-(3-(2H-1,2,3-Triazol-2-yl)benzyl)-2-((5-amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(2,5-difluorobenzyl)-5-fluorospiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(2,2-difluoroethyl)-5-fluorospiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-((1-(fluoromethyl) cyclopropyl)methyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-methylspiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(2-(difluoromethoxy)ethyl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-((3-fluoropyridin-2-yl)methyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(isoxazol-5-ylmethyl) spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-((5-(trifluoromethyl) pyridazin-3-yl)methyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-((1-methyl-1H-indazol-5-yl)methyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(benzo[d]oxazol-2-ylmethyl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(2-(4-fluorophenoxy) ethyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(2-(4-methylthiazol-5-yl)ethyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-((R*)-1-(1-methylcyclopropyl)ethyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1'-(3-cyclopropylprop-2-yn-1-yl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-4-chloro-1'-(4-fluorobenzyl)spiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2'-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1-(4-fluorobenzyl)spiro[pyrrolidine-3,1'-pyrrolo[3,4-c]pyridine]-2,3'(2'H)-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1',7-dimethylspiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-7-methoxy-1'-methylspiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2'-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-1-(4-fluorobenzyl)spiro[pyrrolidine-3,3'-pyrrolo[3,4-c]pyridine]-1',2(2'H)-dione;

(S)-5-Amino-2-((5-fluoro-1'-((1-methylcyclopropyl)methyl)-2',3-dioxospiro[isoindoline-1,3'-pyrrolidin] -2-yl)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carbonitrile;

(S)-2-((5-Amino-6-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1'-(2-(trifluoromethoxy) ethyl)spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione;

(S)-2-((6-Amino-4-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)-5-fluoro-1'-(2,4,5-trifluorobenzyl) spiro[isoindoline-1,3'-pyrrolidine]-2',3-dione; and

(1S,5'S)-2-((5-Amino-6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl)-5-fluoro-1',5'-dimethylspiro [isoindoline-1,3'-pyrrolidine]-2',3-dione;

or a pharmaceutically acceptable salt thereof.

13) The compound or pharmaceutically acceptable salt thereof according to claim 1, which is (*S*)-2-((5-Amino-6-fluoro-1*H*-pyrrolo[3,2-*b*]pyridine-2-yl)methyl)-1'-(but-2-yn-1-yl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione:



,

or a pharmaceutically acceptable salt thereof.

14) The compound according to claim 13, which is (*S*)-2-((5-Amino-6-fluoro-1*H*-pyrrolo[3,2-*b*]pyridine-2-yl)methyl)-1'-(but-2-yn-1-yl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione:



.

15) The pharmaceutically acceptable salt according to claim 13, which is a pharmaceutically acceptable salt of (*S*)-2-((5-Amino-6-fluoro-1*H*-pyrrolo[3,2-*b*]pyridine-2-yl)methyl)-1'-(but-2-yn-1-yl)-5-fluorospiro[isoindoline-1,3'-pyrrolidine]-2',3-dione:



16) A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 and at least one pharmaceutically acceptable excipient.

17) Use of a compound according to any of claims 1 to 15 in the manufacture of a medicine.

18) Use according to claim 17, for the treatment of cancer, optionally wherein the cancer is selected from pancreatic, colorectal, uterine, bile duct, stomach, bladder, cervical, testicular germ cell and non-small cell lung cancer and multiple myeloma, diffuse large B cell lymphoma, rhabdomyosarcoma and cutaneous squamous cell carcinoma.

19) Use according to claim 17, for the treatment of cancer having a MTAP gene deletion, optionally wherein the cancer is selected from pancreatic, colorectal, uterine, bile duct, stomach, bladder, cervical, testicular germ cell and non-small cell lung cancer and multiple myeloma, diffuse large B cell lymphoma, rhabdomyosarcoma and cutaneous squamous cell carcinoma.